- Historical context60th pct
- Peer divergence7.4 robust σ
- Persistence1 period
- Independent evidence1 group
· Services-Medical Laboratories
RESEARCH SNAPSHOTBioNexus Gene Lab Corp's latest supported as-filed period reports revenue of $76,156; gross margin moved 76 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
Unusual transitions and combinations worth inspecting—not forecasts or recommendations.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.33% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -554.77% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -96.63% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 857.31% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 17.05% · CORE
Level · gp.fundamentals.operating_margin
Raw value -370.81% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +51.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Gross margin changed +76 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Gross profit changed -96.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
BGLC · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001520138-26-000349SEC ↗4Aug 14, 2026Period Aug 13, 20260001520138-26-000348SEC ↗4Aug 14, 2026Period Aug 13, 20260001520138-26-000347SEC ↗4Aug 14, 2026Period Aug 13, 20260001520138-26-000346SEC ↗4Aug 14, 2026Period Aug 13, 20260001520138-26-000345SEC ↗10-QAug 14, 2026Period Jun 30, 20260001477932-26-005093SEC ↗8-KJul 28, 2026Period Jul 28, 20260001477932-26-004556SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026Filed Aug 14, 2026 | Tan Lee Su-LengChief Executive Officer | Grant Or AwardDirect | 338,709 | — | — | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 17.95% · OPTIONAL
Inventory changed -46.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Net income changed +53.5% from the comparable as-filed period.
Operating income changed +53.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating margin changed -34377 basis points from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001477932-26-003658